Correction of genetic errors, commonly known as gene editing, holds promise to treat diseases with unmet medical needs. However, gene therapy trials do encounter unwanted outcomes, because of an incomplete understanding of the disease states, and gene therapy processes, among others. This situation encourages a concept that healthcare professionals receiving laboratory research training will not only identify inadequacies in basic biomedical knowledge of gene therapies but also provide tangible refinements. To this end, we have undertaken the PharmD student training in gene editing in a basic research laboratory setting. As a model, MYC gene was chosen for knockout using CRISPR-Cas9 method in HT29 and OVCAR8 cells. Students were involved in the design of MYC-specific gRNAs, subcloning into Cas9-carrying plasmid, and selection of knockout clones from the transfected cells. Subsequently, genomic DNA isolation and sequencing, analysis of clonal DNA sequences using online bioinformatics tools, western blotting, cell proliferation and cell division cycle experiments, were performed to characterize the MYC knockout clones. Results presented in this communication suggest that healthcare professionals who received laboratory training gain a better understanding of the disease states and mechanisms, gene therapy protocols, limitations of gene therapies, ability to critically evaluate the literature and confidence in the oversight of gene therapies in the clinic.
References
[1]
Ahmed, Z., Zeeshan, S., Mendhe, D. and Dong, X. (2020) Human Gene and Disease Associations for Clinical-Genomics and Precision Medicine Research. Clinical and Translational Medicine, 10, 297-318. https://doi.org/10.1002/ctm2.28
[2]
Stenson, P.D., Mort, M., Ball, E.V., Evans, K., Hayden, M., Heywood, S., et al. (2017) The Human Gene Mutation Database: Towards a Comprehensive Repository of Inherited Mutation Data for Medical Research, Genetic Diagnosis and Next-Generation Sequencing Studies. Human Genetics, 136, 665-677.
https://doi.org/10.1007/s00439-017-1779-6
[3]
Dunbar, C.E., High, K.A., Joung, J.K., Kohn, D.B., Ozawa, K. and Sadelain, M. (2018) Gene Therapy Comes of Age. Science, 359, eaan4672.
https://doi.org/10.1126/science.aan4672
[4]
Chandrasegaran, S. and Carroll, D. (2016) Origins of Programmable Nucleases for Genome Engineering. Journal of Molecular Biology, 428, 963-989.
https://doi.org/10.1016/j.jmb.2015.10.014
[5]
Zhang, H., Cheng, Q.X., Liu, A.M., Zhao, G.P. and Wang, J. (2017) A Novel and Efficient Method for Bacteria Genome Editing Employing both CRISPR/Cas9 and an Antibiotic Resistance Cassette. Frontiers in Microbiology, 8, Article No. 812.
https://doi.org/10.3389/fmicb.2017.00812
[6]
Hampton, T. (2020) With First CRISPR Trials, Gene Editing Moves toward the Clinic. JAMA, 323, 1537-1539. https://doi.org/10.1001/jama.2020.3438
[7]
Kan, M.J. and Doudna, J.A. (2022) Treatment of Genetic Diseases with CRISPR Genome Editing. JAMA, 328, 980-981. https://doi.org/10.1001/jama.2022.13468
[8]
Wang, J.Y. and Doudna, J.A. (2023) CRISPR Technology: A Decade of Genome Editing Is Only the Beginning. Science, 379, eadd8643.
https://doi.org/10.1126/science.add8643
[9]
Kratzer, K., Getz, L.J., Peterlini, T., Masson, J.Y. and Dellaire, G. (2022) Addressing the Dark Matter of Gene Therapy: Technical and Ethical Barriers to Clinical Application. Human Genetics, 141, 1175-1193.
https://doi.org/10.1007/s00439-021-02272-5
[10]
Pieczynski, J.N., Deets, A., McDuffee, A. and Lynn Kee, H. (2019) An Undergraduate Laboratory Experience Using CRISPR-cas9 Technology to Deactivate Green Fluorescent Protein Expression in Escherichia coli. Biochemistry and Molecular Biology Education, 47, 145-155. https://doi.org/10.1002/bmb.21206
[11]
Satelli, A., Rao, P.S., Thirumala, S. and Rao, U.S. (2011) Galectin-4 Functions as a Tumor Suppressor of Human Colorectal Cancer. International Journal of Cancer, 129, 799-809. https://doi.org/10.1002/ijc.25750
[12]
Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A. and Zhang, F. (2013) Genome Engineering Using the CRISPR-Cas9 System. Nature Protocols, 8, 2281-2308, Nov. https://doi.org/10.1038/nprot.2013.143
[13]
Vistica, D.T., Skehan, P., Scudiero, D., Monks, A., Pittman, A. and Boyd, M.R. (1991) Tetrazolium-Based Assays for Cellular Viability: A Critical Examination of Selected Parameters Affecting Formazan Production. Cancer Research, 51, 2515-2520.
[14]
Rao, P.S. and Rao, U.S. (2021) Statins Decrease the Expression of c-Myc Protein in Cancer Cell Lines. Molecular and Cellular Biochemistry, 476, 743-755.
https://doi.org/10.1007/s11010-020-03940-2
[15]
Satelli, A., Rao, P.S., Gupta, P.K., Lockman, P.R., Srivenugopal, K.S. and Rao, U.S. (2008) Varied Expression and Localization of Multiple Galectins in Different Cancer Cell Lines. Oncology Reports, 19, 587-594. https://doi.org/10.3892/or.19.3.587
[16]
Rao, U.S. and Rao, P.S. (2017) Surface-Bound Galectin-4 Regulates Gene Transcription and Secretion of Chemokines in Human Colorectal Cancer Cell Lines. Tumor Biology, 39, 1-11. https://doi.org/10.1177/1010428317691687
[17]
Alitalo, K., Schwab, M., Lin, C.C., Varmus, H.E. and Bishop, J.M. (1983) Homogeneously Staining Chromosomal Regions Contain Amplified Copies of an Abundantly Expressed Cellular Oncogene (c-myc) in Malignant Neuroendocrine Cells from a Human Colon Carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 80, 1707-1711.
https://doi.org/10.1073/pnas.80.6.1707
[18]
Gabay, M., Li, Y. and Felsher, D.W. (2014) MYC Activation Is a Hallmark of Cancer Initiation and Maintenance. Cold Spring Harbor Perspectives in Medicine, 4, a014241. https://doi.org/10.1101/cshperspect.a014241
[19]
Gartel, A.L., Ye, X., Goufman, E., Shianov, P., Hay, N., Najmabadi, F., et al. (2001) Myc Represses the p21(WAF1/CIP1) Promoter and Interacts with Sp1/Sp3. Proceedings of the National Academy of Sciences of the United States of America, 98, 4510-4515. https://doi.org/10.1073/pnas.081074898
[20]
Putman, L. (1998) Debate Grows on Safety of Gene-Therapy Vectors. The Lancet, 351, 808. https://doi.org/10.1016/S0140-6736(05)78938-8
[21]
Shirley, J.L., de Jong, Y.P., Terhorst, C. and Herzog, R.W. (2020) Immune Responses to Viral Gene Therapy Vectors. Molecular Therapy, 28, 709-722.
https://doi.org/10.1016/j.ymthe.2020.01.001
[22]
Kelley, W.N. (2012) A Personal Perspective on the Early, Early History of in Vivo (DNA-Based) Gene Therapy. Human Gene Therapy, 23, 541-546.
https://doi.org/10.1089/hum.2012.028
[23]
Wirth, T., Parker, N. and Yla-Herttuala, S. (2013) History of Gene Therapy. Gene, 525, 162-169. https://doi.org/10.1016/j.gene.2013.03.137
[24]
Uddin, F., Rudin, C.M. and Sen, T. (2020) CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Frontiers in Oncology, 10, Article No. 1387. https://doi.org/10.3389/fonc.2020.01387
[25]
Somia, N. and Verma, I.M. (2000) Gene Therapy: Trials and Tribulations. Nature Reviews Genetics, 1, 91-99. https://doi.org/10.1038/35038533
[26]
Rao, P.S., Labhart, M., Mayhew, S.L., Thirumala, S. and Rao, U.S. (2014) Heterogeneity in the Expression of Receptors in the Human Breast Cancer Metastasized to the Brain. Tumor Biology, 35, 7267-7273.
https://doi.org/10.1007/s13277-014-1979-9
[27]
Rao, U.S., Hoerster, N.S., Thirumala, S. and Rao, P.S. (2013) The Influence of Metastatic Site on the Expression of CEA and Cellular Localization of Beta-Catenin in Colorectal Cancer. Journal of Gastroenterology and Hepatology, 28, 505-512.
https://doi.org/10.1111/jgh.12083
[28]
Rao, P.S., Endicott, R., Mullins, R. and Rao, U.S. (2018) A 6-Week Laboratory Research Rotation in Pharmacogenomics: A Model for Preparing Pharmacy Students to Practice Precision Medicine. The Pharmacogenomics Journal, 18, 601-608.
https://doi.org/10.1038/s41397-018-0019-3
[29]
Ruan, W. and Lai, M. (2007) Actin, a Reliable Marker of Internal Control? Clinica Chimica Acta, 385, 1-5. https://doi.org/10.1016/j.cca.2007.07.003
[30]
Kawai, K., Viars, C., Arden, K., Tarin, D., Urquidi, V. and Goodison, S. (2002) Comprehensive Karyotyping of the HT-29 Colon Adenocarcinoma Cell Line. Genes Chromosomes Cancer, 34, 1-8. https://doi.org/10.1002/gcc.10003
[31]
Roschke, A.V., Stover, K., Tonon, G., Schaffer, A.A. and Kirsch, I.R. (2002) Stable Karyotypes in Epithelial Cancer Cell Lines despite High Rates of Ongoing Structural and Numerical Chromosomal Instability. Neoplasia, 4, 19-31.
https://doi.org/10.1038/sj.neo.7900197
[32]
Kosicki, M., Tomberg, K. and Bradley, A. (2018) Repair of Double-Strand Breaks Induced by CRISPR-Cas9 Leads to Large Deletions and Complex Rearrangements. Nature Biotechnology, 36, 765-771. https://doi.org/10.1038/nbt.4192
[33]
Lalonde, S., Stone, O.A., Lessard, S., Lavertu, A., Desjardins, J., Beaudoin, M., et al. (2017) Frameshift Indels Introduced by Genome Editing Can Lead to In-Frame Exon Skipping. PLOS ONE, 12, e0178700.
https://doi.org/10.1371/journal.pone.0178700
[34]
Mou, H., Smith, J.L., Peng, L., Yin, H., Moore, J., Zhang, X.O., et al. (2017) CRISPR/Cas9-Mediated Genome Editing Induces Exon Skipping by Alternative Splicing or Exon Deletion. Genome Biology, 18, Article No. 108.
https://doi.org/10.1186/s13059-017-1237-8
[35]
Rayner, E., Durin, M.A., Thomas, R., Moralli, D., O’Cathail, S.M., Tomlinson, I., et al. (2019) CRISPR-Cas9 Causes Chromosomal Instability and Rearrangements in Cancer Cell Lines, Detectable by Cytogenetic Methods. The CRISPR Journal, 2, 406-416. https://doi.org/10.1089/crispr.2019.0006
